ENTITY
Grifols

Grifols (GRFS US)

41
Analysis
Health Care • Spain
Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
more
•14 Jan 2026 13:45

2025 in Review: Liquid Universe of European Ordinary and Preferred Shares

2025 saw dispersion without repricing in Europe’s dual-class stocks: a stable median hid sharp, liquidity-driven divergences, with convergence...

Share
•19 Jun 2025 00:55

Liquid Universe of European Ordinary and Preferred Shares: June '25 Report

Since mid-May, share price spreads have generally tightened across the European liquid universe of ordinary and preferred shares, with 10...

Share
•19 May 2025 07:30

Liquid Universe of European Ordinary and Preferred Shares: May '25 Report

Since mid-April, share price spreads have generally tightened across the European liquid universe of ordinary and preferred shares, with 10...

Share
bullish•Grifols SA
•16 Apr 2025 18:43

Liquid Universe of European Ordinary and Preferred Shares: April '25 Report

Since mid-March, with sessions of massive volatility, share-price spreads have generally tightened across European liquid universe of ordinary and...

Share
bullish•Grifols SA
•03 Apr 2025 05:30

Blood, Sweat, and Bids: Grifols Draws Renewed Interest from Brookfield

​Brookfield's renewed interest in Grifols signals confidence in its turnaround, with strengthened financials and potential for improved future...

Share
x